RT Journal Article
T1 LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging
A1 Varela Miguéns, Marta
A1 Quintela Vilariño, Carmen
A1 Casado Masa, Sabela
A1 Oliveira Diz, Tadeu de
A1 Müller, Timo D.
A1 Nogueiras Pozo, Rubén
A1 Diéguez González, Carlos
A1 Tovar Carro, Sulay A.
K1 Ghrelin
K1 LEAP2
K1 Aging
K1 High fat diet
K1 Liver
K1 Obesity
K1 Steatosis
AB Scope. Global increase in obesity and metabolic syndrome has led to a marked rise in comorbidities, with liver disease emerging as a major concern. Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over 30% of the population, making it the most prevalent liver disorder worldwide. Hepatic steatosis, hallmark of MAFLD, can progress to inflammation, fibrosis, steatohepatitis, and cirrhosis. Despite advances in elucidating its mechanisms, no effective pharmacological therapy exists to reverse disease progression. Ghrelin signaling axis has been implicated in energy and lipid homeostasis, and the recent identification of liver-expressed antimicrobial peptide 2 (LEAP2) as an endogenous ghrelin receptor antagonist and inverse agonist has generated interest in its potential role in liver metabolism. The primary objective of this study was to evaluate LEAP2 on hepatocyte lipid metabolism and determine its capacity to prevent diet- and age-induced steatosis in vivo. Methods and results. We investigated LEAP2 actions on hepatocyte lipid metabolism using human and mouse hepatocyte cultures, also we did in vivo studies in mice with chronic central LEAP2 administration in models of diet-induced and age-related steatosis. LEAP2 inhibited lipid accumulation in hepatocytes and reduced hepatic lipid deposition in mice fed a standard diet. However, LEAP2 did not prevent high-fat diet–induced steatosis in young mice although it attenuated hepatic inflammation. In aged animals, LEAP2 failed to suppress age-associated inflammation and steatosis. Conclusion. LEAP2 has been identified as a novel regulator of hepatic lipid metabolism with the potential to counteract inflammation-associated steatosis, although its effects on age-related steatosis appear limited. Targeting the LEAP2–ghrelin axis may represent a promising therapeutic strategy; however, further studies are required to determine its efficacy in diet-induced hepatic disease.
PB Elsevier
SN 0024-3205
YR 2026
FD 2026-01-20
LK https://hdl.handle.net/10347/46787
UL https://hdl.handle.net/10347/46787
LA eng
NO Miguéns, M. V., Quintela-Vilariño, C., Casado, S., de Oliveira-Diz, T., Müller, T. D., Nogueiras, R., Diéguez, C., & Tovar, S. (2026). LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging. Life sciences, 388, 124219. https://doi.org/10.1016/j.lfs.2026.124219
NO This work has been supported by grants from Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (ST: PID2020-116741RB-I00; CD: PID2023-149533NB-I00) Xunta de Galicia (RN: ED431C2024/10), Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrici´ on (CIBERobn). CIBERobn is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank financial support from the Consellería de Educación, Ciencia, Universidades e Formación profesional da Xunta de Galicia (Singular Research Centre accreditation ED431G/2023/02) and the European Union (European Regional Development Fund – ERDF) and Ministerio de Ciencia, Innovación y Universidades for the Maria de Maetzu Excellence Accreditation to CIMUS (CEX2024-001463-M).
DS Minerva
RD 22 may 2026